Spero Inks $1.1B Deal for Phase 2-Ready Autoimmune Antibody
SPRO sits 16% above its 52-week low of $1.8.
Summary
Spero Therapeutics licensed global rights (ex-Greater China) to SP001, a Phase 2-ready anti-CD40L antibody, from Innovent Biologics in a deal worth up to $1.1 billion, with up to $1.05 billion in milestones and a $105 million royalty financing. The asset targets IgG4-related disease and other autoimmune conditions, with Spero planning a Phase 2 trial in Q2 2027. This marks a strategic pivot into immunology following the recent FDA approval of Utebzi. The upfront payment and milestone structure add a new pipeline catalyst without immediate dilution, though the $1.1B headline figure is heavily back-loaded. The deal diversifies Spero beyond its infectious disease focus and leverages its development capabilities.
At the time of this announcement, SPRO was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.2M. The 52-week trading range was $1.80 to $3.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.